Questions with a common theme will be selected and answered comprehensively
by our Distinguished Faculty members. Previously answered questions will be
archived for your reference. If you wish to submit a question, click here.

To view current responses, click here.
Question Archive

You may view the responses to previous questions submitted on this site below by clicking on the associated question. The most recent responses appear first.

Question 23 (Response by Jacob Rajfer, MD, and Abraham Morgentaler, MD):
posted 01/23/12

As the number of men living with localized prostate cancer increases, it is important to understand who is a candidate for treatment with testosterone therapy. Dr Rajfer and Dr Morgentaler, could you please provide some insight in this area, focusing on current controversies and safety concerns?

Question 22 (Response by Culley C. Carson III, MD, and Robert A. Kloner, MD, PhD):
posted 12/13/11

As interest in testosterone therapy increases, there is a pressing need to understand the relationship between endogenous and exogenous testosterone and cardiovascular risk. Please review the latest findings regarding this relationship and the implications to clinical practice and future research.

Question 21 (Response by Shehzad S. Basaria, MD, and Jose M. Garcia, MD, PhD):
posted 06/16/11

Recent studies have shown a clear relationship between type 2 diabetes, metabolic syndrome, and hypogonadism. Please discuss the latest findings, in particular the Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (TIMES2) study, and review the potential clinical implications of these studies.

Question 20 (Response by Hossein Sadeghi-Nejad, MD, and Al B. Barqawi, MD, FRCS(Glasg)):
posted 03/22/11

There is some debate over time of serum testosterone evaluation and screening for hypogonadism. Please discuss recent studies that evaluated whether there is substantial blunting of diurnal variation in testosterone levels and the implications. Please describe how these data affect screening patients for hypogonadism in your clinical practice.

Question 19 (Response by Allen D. Seftel, MD, and Andre B. Araujo, PhD): posted 01/30/11
Clinicians may encounter more cases of hypogonadism as the longevity of patients increases and as more comorbid conditions are associated with hypogonadism. Please discuss the role of screening questionnaires and the development of the New England Research Institutes (NERI) hypogonadism screener.

Question 18 (Response by Culley C. Carson III, MD, Jason Hedges, MD, PhD, and Kevin T. McVary, MD): posted 12/30/10
Recent studies have investigated a correlation between lower urinary tract symptoms (LUTS) and endogenous testosterone levels and the effect of exogenous testosterone therapy on LUTS. Please briefly describe these studies and review the potential clinical implications of this research.

Question 17 (Response by John E. Morley, MB, BCh, and Martin M. Miner, MD): posted 9/30/10
Frailty is increasingly acknowledged as a significant geriatric condition. Please describe how frailty manifests within the clinical setting and how it relates to hypogonadism and testosterone therapy. Please review the latest findings regarding the relationship between frailty and hypogonadism and the implications to clinical practice and future research.

Question 16 (Response by Antoine A. Makhlouf, MD, PhD, and Allen D. Seftel, MD): posted 5/27/10
Depression and hypogonadism are associated with erectile dysfunction (ED) and are common in elderly men. Would you describe recent research that explores the relationship between these comorbid conditions and discuss the clinical implications of screening and testosterone therapy?

Question 15 (Response by Shehzad S. Basaria, MD, and Edward D. Kim, MD): posted 2/24/10
The relationship between testosterone levels and cardiovascular disease (CVD) has not been fully elucidated, and concerns persist. What is the relationship between hypogonadism and CVD, and what implications does that relationship present regarding screening for and treating hypogonadism and future research?

Question 14 (Response by Andre T. Guay, MD, and Abdulmaged M. Traish, MBA, PhD): posted 1/26/10
Metabolic syndrome, characterized by a group of risk factors that include abdominal obesity, dyslipidemia, hypertension, and insulin resistance, is a growing health concern. What is the relationship between metabolic syndrome and hypogonadism, and why is it imperative to screen for and treat both conditions?

Question 13 (Response by Richard Sadovsky, MD, and Abraham Morgentaler, MD): posted 8/27/09
A number of testosterone formulations are available to treat male hypogonadism. How do long-acting testosterone formulations affect the treatment of this condition in male hypogonadal patients with differing needs and considerations?

Question 12 (Response by Allen D. Seftel, MD, and Wayne J.G. Hellstrom, MD): posted 5/29/09
The main goals of testosterone therapy are to achieve constant eugonadal testosterone levels and relieve symptoms of hypogonadism for male patients. How do the differentiating properties of each testosterone formulation affect the patient’s therapy choice and optimize outcomes?

Question 11 (Response by Ronald S. Swerdloff, MD, and Robert S. Tan, MD): posted 4/20/09
Hypogonadism is a serious chronic condition associated with chronic comorbidities. What considerations would affect a patient’s long-term adherence to and persistence with testosterone therapy?

Question 10 (Response by Leonard S. Marks, MD, and E. David Crawford, MD): posted 2/27/09
A causal link between testosterone therapy and prostate cancer has not been established. What are the implications of long-term testosterone treatment for male patients with hypogonadism?

Question 9 (Response by Christina Wang, MD): posted 1/09/09
What effects do the various chronic testosterone therapies have on serum testosterone levels?

Question 8 (Response by Adrian S. Dobs, MD): posted 11/04/08
What is the relationship between low testosterone levels and elevated estradiol levels in obese men? What is the impact of elevated estradiol?

Question 7 (Response by Wayne J.G. Hellstrom, MD): posted 06/02/08
Hypogonadism is a chronic clinical condition. What are the potential harms when a patient does not adhere to a regimen of chronic testosterone therapy?

Question 6 (Response by Martin Miner, MD): posted 03/15/08
How do injectable and transdermal testosterone therapies for hypogonadism impact associated psychological symptoms?

Question 5 (Response by Richard Sadovsky, MD): posted 12/15/07
What is the association between obesity and hypogonadism? How will testosterone therapy benefit obese hypogonadal patients?

Question 4 (Response by Frances Hayes, MD): posted 11/15/07
Which factors affect patient adherence with testosterone therapy? How can clinicians promote adherence?

Question 3 (Response by Allen D. Seftel, MD): posted 09/15/07
What is the ideal testosterone therapy for treating patients with hypogonadism?

Question 2 (Response by Abraham Morgentaler, MD): posted 08/15/07
What steps should be taken before and during testosterone therapy to ensure prostate health?

Question 1 (Response by Ridwan Shabsigh, MD): posted 07/05/07
How does testosterone therapy affect cardiovascular risk?

back to top